Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa
- PMID: 21282445
- PMCID: PMC3088216
- DOI: 10.1128/AAC.01390-10
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa
Abstract
ACHN-490 was tested alone and in combination with cefepime, doripenem, imipenem, or piperacillin-tazobactam in a synergy time-kill analysis against 25 Pseudomonas aeruginosa strains with different resistance phenotypes. Each combination was synergistic against most isolates at 24 h, and antagonism was not observed. Combinations of ACHN-490 with cefepime, doripenem, imipenem, or piperacillin-tazobactam yielded synergies in ≥70% and ≥80% of strains at 6 and 12 h, respectively, and in ≥68% at 24 h.
Figures
Similar articles
-
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.J Antimicrob Chemother. 1999 Jul;44(1):91-7. doi: 10.1093/jac/44.1.91. J Antimicrob Chemother. 1999. PMID: 10459815
-
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.Chemotherapy. 2003 Dec;49(6):294-7. doi: 10.1159/000074529. Chemotherapy. 2003. PMID: 14671429
-
In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.Yonsei Med J. 2010 Jan;51(1):111-6. doi: 10.3349/ymj.2010.51.1.111. Epub 2009 Dec 29. Yonsei Med J. 2010. PMID: 20046523 Free PMC article.
-
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].Zhonghua Shao Shang Za Zhi. 2014 Apr;30(2):166-70. Zhonghua Shao Shang Za Zhi. 2014. PMID: 24989663 Chinese.
-
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.Clin Infect Dis. 2017 Apr 1;64(7):972-980. doi: 10.1093/cid/cix034. Clin Infect Dis. 2017. PMID: 28362938 Free PMC article. Review.
Cited by
-
Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.Microb Biotechnol. 2025 Jun;18(6):e70174. doi: 10.1111/1751-7915.70174. Microb Biotechnol. 2025. PMID: 40448301 Free PMC article. Review.
-
A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.Medchemcomm. 2016;7(1):50-68. doi: 10.1039/C5MD00453E. Epub 2015 Nov 19. Medchemcomm. 2016. PMID: 27019689 Free PMC article.
-
The transcriptional regulators of virulence for Pseudomonas aeruginosa: Therapeutic opportunity and preventive potential of its clinical infections.Genes Dis. 2022 Oct 1;10(5):2049-2063. doi: 10.1016/j.gendis.2022.09.009. eCollection 2023 Sep. Genes Dis. 2022. PMID: 37492705 Free PMC article. Review.
-
Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.Future Med Chem. 2013 Jul;5(11):1285-309. doi: 10.4155/fmc.13.80. Future Med Chem. 2013. PMID: 23859208 Free PMC article. Review.
-
Antibiotics and bacterial resistance in the 21st century.Perspect Medicin Chem. 2014 Aug 28;6:25-64. doi: 10.4137/PMC.S14459. eCollection 2014. Perspect Medicin Chem. 2014. PMID: 25232278 Free PMC article. Review.
References
-
- Armstrong E. S., Miller G. H. 2010. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr. Opin. Microbiol. 13:565–573 - PubMed
-
- Briceno D. F., Quinn J. P., Villegas M. V. 2010. Treatment options for multidrug-resistant nonfermenters. Expert Rev. Anti Infect. Ther. 8:303–315 - PubMed
-
- Ferrara A. M. 2006. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int. J. Antimicrob. Agents 27:183–195 - PubMed
-
- Giamarellou H. 2010. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents 36:S50–S54 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical